期刊
PLACENTA
卷 34, 期 8, 页码 719-721出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2013.05.002
关键词
Pravastatin; Placental perfusion; Teratogenic; Cholesterol; Pregnancy
资金
- Canadian Institutes for Health Research
- Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation (Sickkids Hospital)
HMG-CoA reductase inhibitors (statins) are contraindicated during pregnancy. However, it has been suggested that the hydrophilic property of pravastatin prevents its placental transfer to the fetus, explaining neutral effects observed in controlled studies. Using the ex-vivo placental perfusion model, placental transfer of pravastatin (50 ng/ml) was determined. The mean maximum fetal concentration was 4.4 ng/ml. The transfer of pravastatin's across the placenta appears to be limited and slow. Combined with its rapid elimination half-life of 2 h and 50% protein binding, the transfer of pravastatin from maternal to fetal compartments is substantially more limited than observed in the perfusion experiments. (c) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据